Journal of the American Society of Nephrology
2008 JASN IMPACT FACTOR 7.505 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on March 5, 2008
Journal of the American Society of Nephrology
© 2008 American Society of Nephrology
doi: 10.1681/ASN.2008010012
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
ASN.2008010012v1
19/9/1643    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, A. Y.-M.
Right arrow Articles by Lai, K.-N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, A. Y.-M.
Right arrow Articles by Lai, K.-N.

UP FRONT MATTERS

Use of Cardiac Biomarkers in End-Stage Renal Disease

Angela Yee-Moon Wang 1 and Kar-Neng Lai

University Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong


1 To whom correspondence should be addressed. E-mail: aymwang{at}hku.hk.


  Abstract

Mortality among patients with ESRD remains high because of an excessive cardiovascular risk related to a very high incidence of cardiac hypertrophy, cardiomyopathy, heart failure, and coronary artery disease. Identifying serum biomarkers that are useful in profiling cardiovascular risk and enabling stratification of early mortality and cardiovascular risk is an important goal in the treatment of these patients. This review examines current evidence pertaining to the role and utility of two emerging cardiac biomarkers, B-type natriuretic peptide and cardiac troponin T, in patients with ESRD. Together, these data demonstrate how these two cardiac biomarkers may play an adjunctive role to echocardiography in assessing cardiovascular risk and how they may aid in the clinical treatment of these patients.


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
E. W. Kang, H. J. Na, S. M. Hong, S. K. Shin, S.-W. Kang, K. H. Choi, H. Y. Lee, D.-S. Han, and S. H. Han
Prognostic value of elevated cardiac troponin I in ESRD patients with sepsis
Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1568 - 1573.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673